Novo Nordisk’s novel amylin-targeting obesity drug amycretin showed substantial weight loss in phase 1/2 trials, achieving up to 24.3% body weight reduction at the highest dose. However, similar efficacy across multiple doses and high side-effect rates raise questions about optimal dosing strategies. Results, published in The Lancet and presented at ADA 2025, indicate a non-dose-dependent response, an uncommon finding necessitating further investigation to determine the most effective and tolerable treatment regimen going forward.